-
1
-
-
77954197187
-
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes mellitus: A randomized double-blind trial
-
Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes mellitus: a randomized double-blind trial. Diabetes Obes Metab 2010, 12: 613-22.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 613-622
-
-
Iwamoto, Y.1
Tajima, N.2
Kadowaki, T.3
-
2
-
-
38349126264
-
Efficacy and safety of sitaglip - Tin monotherapy in Japanese patients with type 2 diabetes
-
Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitaglip - tin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79: 291-8.
-
(2008)
Diabetes Res Clin Pract
, vol.79
, pp. 291-298
-
-
Nonaka, K.1
Kakikawa, T.2
Sato, A.3
-
3
-
-
84859016755
-
Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control
-
Tajima N, Kadowaki T, Odawara M, et al. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int 2011, 2: 32-44.
-
(2011)
Diabetol Int
, vol.2
, pp. 32-44
-
-
Tajima, N.1
Kadowaki, T.2
Odawara, M.3
-
4
-
-
33846006173
-
GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes
-
Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006, 368: 1696-705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
5
-
-
33845344395
-
Plasma insulin response to oral and intravenous glucose administration
-
Elrick H, Stimmler L, Hland CJ jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24: 1076-82.
-
(1964)
J Clin Endocrinol Metab
, vol.24
, pp. 1076-1082
-
-
Elrick, H.1
Stimmler, L.2
Hland Jr., C.J.3
Arai, Y.4
-
7
-
-
84355162099
-
ASSET-K Study group the safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes
-
Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I; ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012, 95: e20-2.
-
(2012)
Diabetes Res Clin Pract
, vol.95
, pp. 20-22
-
-
Maeda, H.1
Kubota, A.2
Tanaka, Y.3
Terauchi, Y.4
Matsuba, I.5
-
8
-
-
84885612196
-
Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
-
in press
-
Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Invest (in press).
-
J Diabetes Invest
-
-
Kubota, A.1
Maeda, H.2
Kanamori, A.3
-
9
-
-
84878065126
-
Pleotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients
-
Kubota A, Maeda H, Kanamori A, et al. Pleotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012, 4: e309-13.
-
(2012)
J Clin Med Res
, vol.4
, pp. 309-313
-
-
Kubota, A.1
Maeda, H.2
Kanamori, A.3
-
10
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35: 1364-79.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
11
-
-
78651338445
-
Standard of medical care in diabetes- 2011
-
American Diabetes Association
-
American Diabetes Association. Standard of medical care in diabetes- 2011. Diabetes Care 2011, 34 (Suppl. 1): S11-61.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 1
, pp. 11-61
-
-
-
12
-
-
79956326006
-
Dipeptidyl peptidase- 4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials
-
Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase- 4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13: 594-603.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
-
13
-
-
84859097891
-
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
-
Tajiri Y, Munehisa T, Ohki T, et al. Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J 2012, 59: e197-204.
-
(2012)
Endocr J
, vol.59
, pp. 197-204
-
-
Tajiri, Y.1
Munehisa, T.2
Ohki, T.3
-
14
-
-
0032856829
-
Heterogeneous relationship of early insulin response and fasting insulin level with development of noninsulin- dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity
-
Yoshinaga H, Kosaka K. Heterogeneous relationship of early insulin response and fasting insulin level with development of noninsulin- dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Diabetes Res Clin Pract 1999, 44: 129-36.
-
(1999)
Diabetes Res Clin Pract
, vol.44
, pp. 129-136
-
-
Yoshinaga, H.1
Kosaka, K.2
-
15
-
-
77954731903
-
Present status of sulfonylurea treatment for type 2 diabetes in Japan: Second report of a cross-sectional survey of 15,652 patients
-
Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. Endocr J 2010, 57: 499-507.
-
(2010)
Endocr J
, vol.57
, pp. 499-507
-
-
Arai, K.1
Matoba, K.2
Hirao, K.3
-
16
-
-
84867752550
-
Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
-
Iwasaki M, Hoshian F, Tsuji T, et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest 2012, 3: 464-7.
-
(2012)
J Diabetes Invest
, Issue.3
, pp. 464-467
-
-
Iwasaki, M.1
Hoshian, F.2
Tsuji, T.3
-
17
-
-
0032812996
-
Food intake patterns and 25-year mortality from coronary heart disease: Cross-cultural correlations in the Seven Countries Study
-
The Seven Countries Study Research Group
-
Menotti A, Kromhout D, Blackburn H, et al. Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. The Seven Countries Study Research Group. Eur J Epidemiol 1999, 15: 507-15.
-
(1999)
Eur J Epidemiol
, vol.15
, pp. 507-515
-
-
Menotti, A.1
Kromhout, D.2
Blackburn, H.3
-
18
-
-
48449093468
-
Separate impact of obesity and glucose tolerance on the incretin effect in normal subject and type 2 diabetic patients
-
Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subject and type 2 diabetic patients. Diabetes 2008, 57: 1340-8.
-
(2008)
Diabetes
, vol.57
, pp. 1340-1348
-
-
Muscelli, E.1
Mari, A.2
Casolaro, A.3
-
19
-
-
40949090627
-
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
-
Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57: 678-87.
-
(2008)
Diabetes
, vol.57
, pp. 678-687
-
-
Vollmer, K.1
Holst, J.J.2
Baller, B.3
-
20
-
-
79952310049
-
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?
-
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011, 54: 10-8.
-
(2011)
Diabetologia
, vol.54
, pp. 10-18
-
-
Nauck, M.A.1
Vardarli, I.2
Deacon, C.F.3
Holst, J.J.4
Meier, J.J.5
-
21
-
-
58149467276
-
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagonlike peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
-
Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagonlike peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52: 199-20.
-
(2009)
Diabetologia
, vol.52
, pp. 199-130
-
-
Højberg, P.V.1
Vilsbøll, T.2
Rabøl, R.3
|